Can Dual-Targeted CAR-T Break the Solid-Tumor Barrier in Colorectal Cancer?: FDA News | September 2026

What’s New?

The FDA has cleared a first-in-human trial of an experimental dual-targeted CAR T-cell therapy developed for advanced colorectal cancer, with clinical testing expected to begin in December.

The engineered T cells target B7-H3, which is expressed across many colorectal cancers.

The strategy simultaneously targets the IL-8 pathway, implicated in tumor growth, spread and the immunosuppressive tumor microenvironment.

This dual approach is designed to help CAR-T cells overcome key barriers that have limited their success in solid tumors.

The initial trial will primarily determine safety and feasibility, while exploring early antitumor activity.

If successful, the platform could potentially be investigated in other B7-H3/IL-8–relevant solid tumors.

Why Does It Matter?

CAR-T therapy has transformed several hematological malignancies but has struggled in colorectal and other solid cancers. Dual targeting represents an innovative attempt to overcome tumor heterogeneity and microenvironmental resistance.

GastroAGI Takeaway

Exciting science, but far too early for clinical conclusions. FDA clearance means permission to begin human testing—not FDA approval of the therapy. For now, this is highly promising, hypothesis-generating translational oncology; safety and meaningful efficacy in patients remain to be demonstrated.